Do GLP-1 drugs show pancreatitis safety signals?
Across 6,751 FAERS ICSRs (plus 39 case-series patients), AP reporting signals appeared for all studied GLP-1 RAs, especially exenatide and liraglutide.
Source
Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
Study at a glance
- Design
- Other — Case series plus FAERS disproportionality pharmacovigilance for GLP-1 RA–associated AP
- N
- N=6751 · 6,751 FAERS ICSRs; case series n=39 AP events
- Population
- FAERS reports and case-series patients with AP while on GLP-1 RAs
- Outcome
- Disproportionality signals for acute pancreatitis across GLP-1 RA agents
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Reviewed AP case reports and mined FAERS (2005–2023) with ROR/PRR/BCPNN/MGPS for seven GLP-1 RAs including tirzepatide.
What they found
Median age 57; 98.3% of FAERS cases serious. AP signals across agents, with emphasis on exenatide and liraglutide.
The limits
What it doesn't show
Spontaneous reporting signals are not incidence rates or proof of causality vs confounding by indication.
Key terms
- GLP-1 RA
- Glucagon-like peptide-1 receptor agonist diabetes/weight drug class.
- Acute pancreatitis (AP)
- Acute pancreatic inflammation adverse event studied here.
- FAERS
- FDA Adverse Event Reporting System database.
- ROR/PRR
- Disproportionality metrics for reporting signals.
- ICSR
- Individual case safety report in FAERS.
- Pharmacovigilance
- Post-marketing safety signal detection.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
FAERS ICSRs analyzed:
Common questions
FAERS ICSRs?
6,751.
Case series n?
39 AP patients.
Median age / serious %?
57 years; 98.3% serious.
Strongest emphasis?
Exenatide and liraglutide.
More on Diabetes